Forty Seven, Inc.
(NASDAQ : FTSV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. 3.04%92.771.9%$1227.50m
JNJJohnson & Johnson 1.11%148.600.7%$1059.48m
BMYBristol-Myers Squibb Co. -0.15%59.721.0%$1024.94m
PFEPfizer Inc. -0.16%38.120.9%$854.75m
MRKMerck & Co., Inc. 2.10%80.700.7%$839.97m
LLYEli Lilly & Co. 1.71%153.221.1%$505.05m
AZNAstraZeneca Plc 2.04%54.591.2%$279.84m
NVSNovartis AG 1.39%87.480.2%$155.07m
GSKGlaxoSmithKline Plc 0.96%41.940.2%$138.99m
NVONovo Nordisk A/S 1.52%65.950.1%$91.79m
SNYSanofi 0.88%49.110.2%$75.33m
RGENRepligen Corp. 1.36%130.977.1%$69.36m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 8.29%62.590.0%$47.83m
TPTXTurning Point Therapeutics, Inc. 0.99%69.250.0%$40.47m
ARCTArcturus Therapeutics Holdings, Inc. 5.99%38.940.0%$37.16m

Company Profile

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a ''don't eat me'' signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.